No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
Helmut ButzkuevenLudwig KapposTim SpelmanMaria TrojanoHeinz WiendlRay SuShirley LiaoRobert HydeStephanie LicataPei-Ran HoNolan CampbellPublished in: Therapeutic advances in neurological disorders (2021)
NCT00493298.